In addition, ASTN treatment significantly reduces the frequency and cell number of activated HSCs or myofibroblast in the NASH liver, resulting in a reduction in liver fibrosis. This evidence concerns the gene ASTN1 and metabolic dysfunction-associated steatohepatitis.